The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHZD.L Regulatory News (HZD)

  • There is currently no data for HZD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Board Changes

1 May 2020 07:00

RNS Number : 5800L
Horizon Discovery Group plc
01 May 2020
 

Horizon Discovery Group plc

 

 Board Changes 

 

Cambridge, UK, 1 May 2020: Horizon Discovery Group plc (LSE: HZD) ("Horizon" or "the Group"), a cell engineering company focused on commercialising the application of gene editing and gene modulation to accelerate scientific innovation and biopharmaceutical drug development, today announces the appointment of Dr. Siddhartha Kadia as Non-Executive Director, with effect from 30 April 2020. The Group also announces that Dr. Susan Galbraith stood down from her position as a Non-Executive Director of the Board, with effect from 30 April 2020.

Dr. Kadia has a deep background in executive management and public company governance across a range of global businesses, predominantly in the Life Sciences Tools, Diagnostics and Medical Technologies, High Tech and TIC (Testing, Inspection and Certification) industries. Dr. Kadia was formerly President and CEO of EAG Laboratories until its acquisition by Eurofins Scientific in 2017. He continued to serve as the CEO of EAG laboratories until December 2018. Prior to EAG, he served in a number of senior roles including as President of Life Sciences Division at Life Technologies Corporation at the time of its acquisition by ThermoFisher Scientific in February 2014.

 

Dr. Kadia has extensive Board experience and has previously served as a Director of two US listed companies, Newport Corporation (NSDQ: NEWP), Volcano Corporation (NSDQ: VOLC) and of privately owned EAG Laboratories. He currently serves on the Board of Directors of ALS Limited, an ASX listed public global TIC company headquartered in Australia, and was appointed in February 2020 to the Board of Bioskryb, a private company that is developing genomic amplification technologies that deliver higher coverage and fidelity for gene sequencing. He previously served as a management consultant at McKinsey and Company. Dr. Kadia has executive experience leading businesses in the US, Europe, Japan and China and has an extensive global network in scientific enterprise.

 

Dr. Kadia obtained his Ph.D. in biomedical engineering from Johns Hopkins University, followed by a post-doctoral fellowship at Johns Hopkins University School of Medicine, Baltimore. He also holds a M.S. in biomedical engineering from Rutgers University, New Jersey, and a B.E in electronics and telecommunications from Gujarat University in India.

Dr. Susan Galbraith has served on the Board of Horizon Discovery since 2014, bringing extensive insight into therapeutic research and development. Dr. Galbraith is currently Senior Vice President and Head of Early Oncology at AstraZeneca. Her departure from the Group's Board reflects her increased responsibilities at AstraZeneca.

Dr. Ian Gilham, Non-Executive Chairman of Horizon, commented:

"We are delighted to welcome Siddhartha to the Board. He brings a wealth of US public company experience and international expertise in the life sciences tools arena across global markets with a particular emphasis on North America, Asia and Europe.

"At the same time, on behalf of my colleagues, I would like to thank Susan for her outstanding contributions and commitment to the Group since her appointment in 2014. We wish her every success in the future."

Dr. Kadia commented:

"It is an exciting time for Horizon Discovery Group, with its global leadership in gene modulation and gene editing technologies. I am thrilled to be part of the Horizon team and join the Group in its mission to drive the next wave of precision medicine."

Dr. Galbraith added:

"I have thoroughly enjoyed my six years on the Board at Horizon. Horizon's technology portfolio is unparalleled, and I wish all of the staff and my former colleagues around the Board table well."

The following information regarding the appointment of Dr. Siddhartha Chandrakant Kadia, aged 50, is disclosed in accordance with Rule 17 and paragraph (g) of Schedule 2 of the AIM rules.

Current directorships/partnerships:

Non-Executive Independent Director, ALS Limited

Director, Bioskryb

Previous directorships/ partnerships held in the past five years:

President/CEO and Director, EAG Laboratories

Director, EAG Inc

Director, Evans Analytical Group LLC

Director, EAG Holdings LLC

Director, Newport Corporation

Director, Volcano Corporation

 

Ends

 

For further information from Horizon Discovery Group plc, please contact:

 

Horizon Discovery Group plc

Terry Pizzie, Chief Executive Officer

Jayesh Pankhania, Chief Financial Officer

Jon Davies, Head of Investor Relations

Tel: +44 (0) 1223 655 580

 

Numis Securities Limited (Broker and NOMAD)

Freddie Barnfield / Duncan Monteith

Tel: +44 (0) 207 260 1000

 

Consilium Strategic Communications (Financial Media and UK Investor Relations)

Mary-Jane Elliott / Matthew Neal / Melissa Gardiner

Tel: +44 (0) 20 3709 5700

Email: horizon@consilium-comms.com

 

Zyme Communications (Trade and Regional Media)

Katie Odgaard

Tel: +44 (0)7787 502 947

Email: katie.odgaard@zymecommunications.com 

 

Westwicke, an ICR Company (US Investor Relations)

Stephanie Carrington

Tel. +1 646-277-1282

Email: horizondisovery@icrinc.com

 

 

About Horizon Discovery Group plc www.horizondiscovery.com

 

Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a cell engineering company focused on commercializing the application of gene editing and gene modulation to accelerate scientific innovation and biopharmaceutical drug development. Horizon's portfolio of tools and services is built on decades of experience in altering the expression of genes across mammalian and human cell types to provide cell engineering tools and services to customers in three key areas of the therapeutic ecosystem: basic research, drug discovery and development and therapeutic applications. Horizon's offerings support and enable critical elements of the drug development and therapeutic value chain, particularly in the area of precision medicine. Horizon's customers include biopharmaceutical and diagnostics companies, contract research and manufacturing organizations and academic researchers across the globe.

 

Horizon is headquartered in Cambridge, UK with offices in USA and Japan. The Group is listed on the London Stock Exchange's AIM market under the ticker HZD.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOASDDESSESSEDL
Date   Source Headline
16th Jan 20177:00 amRNSHorizon broadens gene editing capabilities
13th Jan 20177:00 amRNSAdditional Listing
6th Jan 20171:24 pmRNSAdditional Listing
29th Dec 201610:28 amRNSHolding(s) in Company
15th Dec 20167:00 amRNSAdditional Listing
2nd Dec 201611:30 amRNSDirector/PDMR Shareholding
2nd Dec 201610:00 amRNSDirector Dealings
16th Nov 20167:00 amRNSHZD Enters Chinese Clinical Diagnostics Market
14th Nov 20167:00 amRNSAdditional Listing
9th Nov 20167:00 amRNSOEM Agreement with CareDx for Reference Standards
1st Nov 20167:00 amRNSProgress Update: Molecular Screening Platform
31st Oct 201612:36 pmRNSAdditional Listing
19th Oct 20167:00 amRNSLicensing Agreement: Biomanufacturing Cell Lines
10th Oct 20167:00 amRNSAdditional Listing
30th Sep 20163:25 pmRNSHolding(s) in Company
30th Sep 20167:00 amRNSAdditional Listing
23rd Sep 20161:46 pmRNSHolding(s) in Company
21st Sep 20165:28 pmRNSHolding(s) in Company
20th Sep 20167:00 amRNSInterim Results for Six Months Ended 30 June 2016
13th Sep 20169:04 amRNSHolding(s) in Company
13th Sep 20167:00 amRNSBiomanufacturing Cell Lines Licensed to CPI, NIBRT
12th Sep 201611:04 amRNSHolding(s) in Company
7th Sep 201612:19 pmRNSHolding(s) in Company
7th Sep 20167:02 amRNSNotice of Interim Results
7th Sep 20167:00 amRNSAdditional Listing
6th Sep 201612:31 pmRNSHolding(s) in Company
6th Sep 20167:00 amRNSCRISPR Collaboration with Fulcrum Therapeutics
1st Sep 20167:00 amRNSHZD and Ventana Sign Reference Standards Agreement
18th Aug 20167:00 amRNSAdditional Listing
16th Aug 20164:09 pmRNSHolding(s) in Company
3rd Aug 20163:26 pmRNSHolding(s) in Company
29th Jul 20163:31 pmRNSHolding(s) in Company
28th Jul 20167:00 amRNSHorizon Discovery Group Issue of Equity
26th Jul 201610:47 amRNSAdditional Listing
21st Jul 20169:11 amRNSAdditional Listing
13th Jul 20161:20 pmRNSHoldings in Company
7th Jul 20169:17 amRNSHoldings in Company
4th Jul 20164:33 pmRNSHoldings in Company
29th Jun 20164:01 pmRNSAdditional Listing
28th Jun 20167:00 amRNSAdditional Listing
24th Jun 201611:20 amRNSResult of AGM
9th Jun 20162:21 pmRNSGrant of Options
7th Jun 20165:19 pmRNSAnnual Report and Notice of Annual General Meeting
3rd Jun 20167:00 amRNSAdditional Listing
1st Jun 20167:00 amRNSReference Standards used in QIAGEN NGS System
12th May 20167:00 amRNSOEM Agreements with Market Leading NGS Company
11th May 20167:00 amRNSAdditional Listing
28th Apr 20167:45 amRNSAdditional Listing
26th Apr 20167:35 amRNSPreliminary Results for the Year Ended 31 Dec 2015
19th Apr 20167:00 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.